Clinicopathological, Molecular, and DNA Methylation Analysis of Ossifying Fibromyxoid Tumors Delineates the ZC3H7B::BCOR Subset as a Distinct Entity
Modern Pathology · 2026-08 · 39 (8) · 101025
DOI: 10.1016/j.modpat.2026.101025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2026-08. Verfasst von Natálie Klubíčková und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Faculty of Medicine in Plzen, Charles University, Prague, Czech Republic; Bioptická Laboratory Ltd., Plzen, Czech Republic; …. Hauptthemen laut MEDLINE: DNA Methylation, Repressor Proteins, Proto-Oncogene Proteins, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charles University, Ministry of Education Youth and Sports of the Czech Republic, European Commission.
Abstract (Originalsprache)
Ossifying fibromyxoid tumor (OFMT) is a rare mesenchymal neoplasm of uncertain lineage of differentiation driven by a broad spectrum of gene fusions. It manifests primarily in soft tissues of the extremities. In this study, we performed a comprehensive clinicopathological, molecular-genetic, and epigenetic analysis of 70 cases of OFMT, with a specific focus on rare fusion subtypes, particularly ZC3H7B::BCOR, PHF1::TFE3, and MEAF6::PHF1. In addition, we included 7 tumors with novel fusions, namely, AFF3::PHF1, PHF1::KLF15, PHF1::PRKAG1, CREBBP::PHF1, EPC1::BMI1, MEAF6::BCOR, and EP300::BCORL1. The clinicopathological characteristics revealed a correlation between specific fusions and aggressive clinical behavior; notably, tumors with ZC3H7B::BCOR fusions were always classified as morphologically atypical or malignant and were associated with significantly higher recurrence and metastatic rates compared with other fusion groups, particularly EP400::PHF1. Immunohistochemical analysis further revealed a distinct immunophenotype in the ZC3H7B::BCOR group. Whereas immunopositivity for cytokeratins and myogenic markers was observed in approximately one-quarter and more than one-third of OFMT cases overall, respectively, ZC3H7B::BCOR-rearranged tumors were negative for both. In contrast, the majority showed immunopositivity for pan-Trk. Additionally, DNA methylation profiling distinguished ZC3H7B::BCOR-rearranged cases from other fusion-positive OFMT cases. The former group clustered closely with a subset of high-grade endometrial stromal sarcomas. This study supports the recognition of ZC3H7B::BCOR-positive tumors as a distinct clinicopathological entity, contributing to the refined molecular taxonomy of this neoplasm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Faculty of Medicine in Plzen, Charles University, Prague, Czech Republic; Bioptická Laboratory Ltd., Plzen, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University,…
- Soft Tissue and Bone Pathology Section, Department of Pathology, Cleveland Clinic, Cleveland, Ohio.
- Bone Tumor Reference Center, Institute for Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
- Bioptická Laboratory Ltd., Plzen, Czech Republic.
- Bioptická Laboratory Ltd., Plzen, Czech Republic; Department of Biology and Medical Genetics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
- Department of Biopathology, Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.
Förderung
- Charles University
- Ministry of Education Youth and Sports of the Czech Republic
- European Commission
Zitieren
APA
Klubíčková, N., Dermawan, J. K., Ameline, B., Martínek, P., Vaněček, T., Hájková, V., Ptáková, N., Grossmann, P., Šteiner, P., Kormunda, S., Perret, R. E., Le Loarer, F., Dehner, C. A., Torres-Mora, J., Gross, J. M., Chrisinger, J. S. A., Charville, G., Kösemehmetoĝlu, K., Wangsiricharoen, S., …, & Michal, M. (2026). Clinicopathological, Molecular, and DNA Methylation Analysis of Ossifying Fibromyxoid Tumors Delineates the ZC3H7B::BCOR Subset as a Distinct Entity. Modern Pathology, 39(8), 101025. https://doi.org/10.1016/j.modpat.2026.101025
Vancouver
Klubíčková N, Dermawan JK, Ameline B, Martínek P, Vaněček T, Hájková V, et al. Clinicopathological, Molecular, and DNA Methylation Analysis of Ossifying Fibromyxoid Tumors Delineates the ZC3H7B::BCOR Subset as a Distinct Entity. Modern Pathology. 2026;39(8):101025. doi:10.1016/j.modpat.2026.101025
BibTeX
@article{Klubkov2026,
author = {Klubíčková, Natálie and Dermawan, Josephine K and Ameline, Baptiste and Martínek, Petr and Vaněček, Tomáš and Hájková, Veronika and Ptáková, Nikola and Grossmann, Petr and Šteiner, Petr and Kormunda, Stanislav and Perret, Raul E and Le Loarer, François and Dehner, Carina A and Torres-Mora, Jorge and Gross, John M and Chrisinger, John S A and Charville, Gregory and Kösemehmetoĝlu, Kemal and Wangsiricharoen, Sintawat and Meis, Jeanne and Špůrková, Zuzana and Zámečník, Michal and Staniczková Zambo, Iva and Klinger, Tomáš and Švajdler, Marián and Kinkor, Zdeněk and Michalová, Květoslava and Baumhoer, Daniel and Michal, Michal and Antonescu, Cristina R and Michal, Michael},
title = {Clinicopathological, Molecular, and DNA Methylation Analysis of Ossifying Fibromyxoid Tumors Delineates the ZC3H7B::BCOR Subset as a Distinct Entity},
journal = {Modern Pathology},
year = {2026},
volume = {39},
number = {8},
pages = {101025},
doi = {10.1016/j.modpat.2026.101025}
}
EUVIMED